Vancomycin vs Teicoplanin: What the Research Compares

What this comparison covers

Vancomycin and teicoplanin are prescription glycopeptide antibiotics given under medical supervision, most often in hospital settings. Both are discussed in the same body of literature because they share a chemical class and a cell wall target, and because resistance genes described in enterococci and staphylococci can affect susceptibility to one or both agents, as researchers reported in a study of vancomycin- and teicoplanin-resistant Enterococcus faecium carrying a vanD5 genomic island (PMID 32585683). This page summarises what published studies describe about each agent and places those evidence bases next to one another. It does not rank them, does not say which situation suits which drug, and contains no dosing directions.

This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about any antibiotic, including questions about selection, monitoring and administration.

Head-to-head randomized trials: what the verified citation set contains

Stated plainly: the verified citation set behind this page contains no head-to-head randomized controlled trial that enrolled patients, assigned them to a vancomycin arm or a teicoplanin arm, and reported a prespecified primary endpoint. No trial name, population, arm or endpoint result can therefore be presented here, because inventing one would misrepresent the record.

The closest comparative documents in the set are two paired reviews published in the Journal of Chemotherapy in 2000. One review examined the comparative safety of teicoplanin and vancomycin (PMID 11131960), and the companion review examined the comparative pharmacokinetics of the two agents (PMID 11131959). Reviews of this kind synthesise earlier published data rather than generating new randomized comparisons, and that distinction matters when readers weigh how strong a comparison is. Readers looking for individual randomized trials, including any published after these reviews, can search PubMed directly or ask a clinician or hospital pharmacist familiar with the relevant guidelines.

Side by side: the separate evidence bases

Class and mechanism

Both agents belong to the glycopeptide class, a group of large, structurally complex natural product antibiotics that act on the bacterial cell wall of Gram-positive organisms. A 2003 review traced how vancomycin is assembled in nature, describing the enzymatic steps that build its cross-linked heptapeptide core (PMID 12596194). A 2000 review of teicoplanin chemistry and microbiology described teicoplanin as a complex of related glycopeptide components and summarised its antibacterial profile (PMID 11131964).

Because the two share a target, they also share vulnerability to the same families of resistance determinants. A 2008 review described the VanS/VanR two component systems that sense glycopeptide exposure and switch on resistance gene expression in enterococci (PMID 18792691). Different van gene clusters produce different susceptibility patterns, which is why some isolates test resistant to one glycopeptide and not the other, while others, such as the vanD5-carrying E. faecium described in 2020, were reported resistant to both vancomycin and teicoplanin (PMID 32585683).

Pharmacokinetics: what the comparative review reports

The single document in this citation set that directly contrasts the two agents on drug handling is the 2000 Journal of Chemotherapy review of comparative pharmacokinetics of teicoplanin and vancomycin (PMID 11131959). Pharmacokinetic differences between glycopeptides are one reason hospital protocols specify different monitoring approaches, and the review frames these parameters as inputs to clinical decision making rather than as instructions for patients. A separate 2024 review examined teicoplanin specifically in the peritoneal dialysis population, covering efficacy, safety and pharmacological considerations relevant to that setting (PMID 39118702). No dose figures are reproduced on this page; dosing decisions, including any adjustment for kidney function or dialysis, belong with the prescribing clinician and the applicable national product labelling.

Resistance and surveillance literature

Resistance is where the comparative literature is most active. The 2008 review of VanS/VanR signalling explained how the regulatory sensor kinase and response regulator pairs control inducible glycopeptide resistance (PMID 18792691). A 2020 report in the Journal of Antimicrobial Chemotherapy described the emergence of vancomycin- and teicoplanin-resistant Enterococcus faecium carrying vanD5 on a large genomic island (PMID 32585683). A 2022 surveillance study of hospitalised patients in Germany characterised glycopeptide resistance in Enterococcus species and coagulase-negative staphylococci and also reported dalbavancin susceptibility among those isolates (PMID 34958996).

Stewardship research also touches both agents. A 2020 prospective study at a large academic hospital examined prescriptions of teicoplanin judged inappropriate and discussed the implications for antimicrobial resistance (PMID 32489961). Papers of this type address prescribing systems and institutional practice, not individual patient instructions.

Other published research lines

• Clostridioides difficile laboratory work. A 2021 study in Antibiotics reported that teicoplanin suppressed vegetative C. difficile and spore outgrowth in laboratory conditions (PMID 34439034).
• Semisynthetic derivatives. Researchers synthesised perfluoroalkyl derivatives of teicoplanin and vancomycin and evaluated antiviral activity in a 2020 medicinal chemistry paper (PMID 32652783). Such derivatives are laboratory compounds distinct from the licensed medicines.
• Delivery platforms. A 2022 review in Biotechnology Advances surveyed nanoantibiotic strategies aimed at multidrug resistant Gram-positive infections and the open questions around them (PMID 35337933).

Adverse events: What Studies Report

The 2000 Journal of Chemotherapy review of comparative safety of teicoplanin and vancomycin is the document in this set that places adverse event profiles for the two agents alongside one another (PMID 11131960). The 2024 review of teicoplanin in peritoneal dialysis also addressed safety considerations within that specific population (PMID 39118702). Readers comparing tolerability should note that a review published in 2000 reflects the evidence available at that time and that current product labelling, hospital protocols and newer pharmacovigilance data supersede it for clinical purposes. Anyone who experiences a reaction during treatment should contact the treating clinician rather than relying on summary pages.

Regulatory status

Vancomycin is an approved prescription antibiotic with marketing authorisation in the United States and in many other countries. Teicoplanin is an approved prescription antibiotic in numerous countries across Europe, Asia and other regions, and its availability is set jurisdiction by jurisdiction; the 2020 prospective prescribing study was conducted in a hospital where teicoplanin was part of routine formulary use (PMID 32489961). For both agents, the authoritative source for indications, administration and monitoring is the product labelling approved by the relevant national regulator, interpreted by a prescribing clinician.

How to read this comparison

1. Comparative reviews summarise prior data; they carry different evidentiary weight than randomized head-to-head trials, and the 2000 safety and pharmacokinetic reviews are the comparative documents available in this set (PMID 11131960, PMID 11131959).
2. Laboratory and genomic findings, such as the vanD5 island report, describe isolates and mechanisms rather than patient outcomes (PMID 32585683).
3. Susceptibility patterns are local; surveillance data from one country, such as the 2022 German hospital survey, do not transfer automatically elsewhere (PMID 34958996).

Related reading

• Vancomycin: what the literature describes
• Teicoplanin: what the literature describes

References

• Comparative pharmacokinetics of teicoplanin and vancomycin (Journal of Chemotherapy, 2000)
• Comparative safety of teicoplanin and vancomycin (Journal of Chemotherapy, 2000)
• Teicoplanin Chemistry and Microbiology (Journal of Chemotherapy, 2000)
• Vancomycin assembly: nature's way (Angewandte Chemie International Edition, 2003)
• Vancomycin resistance VanS/VanR two-component systems (Advances in Experimental Medicine and Biology, 2008)
• Prospective Study of Irrational Prescription of Teicoplanin in a Large Academic Hospital: A Dilemma of Antimicrobial Resistance (Journal of Research in Pharmacy Practice, 2020)
• Emergence of vancomycin- and teicoplanin-resistant Enterococcus faecium via vanD5-harbouring large genomic island (Journal of Antimicrobial Chemotherapy, 2020)
• Synthesis of Antiviral Perfluoroalkyl Derivatives of Teicoplanin and Vancomycin (ChemMedChem, 2020)
• Teicoplanin Suppresses Vegetative Clostridioides difficile and Spore Outgrowth (Antibiotics, 2021)
• Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany (Journal of Global Antimicrobial Resistance, 2022)
• Nanoantibiotics to fight multidrug resistant infections by Gram-positive bacteria: hope or reality? (Biotechnology Advances, 2022)
• Teicoplanin in peritoneal dialysis: efficacy, safety, and pharmacological considerations (Annals of Medicine and Surgery, 2024)